Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of BIIB054 in early Parkinson's disease
MOH_2018-06-24_002475Phase 2Completed
- Sponsor
- Biogen
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cinpanemab in Parkinson's disease (PD) (4 arms), sponsored by Biogen. Primary endpoint: Safety of BIIB054. Started Apr 2018; status: completed.
02
Drugs
cinpanemab
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on MOH_2018-06-24_002475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-06-24_002475.